Product Information
RISPERIDONE ER 37.5 MG VIAL is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $565.9133 per EA under NDC 00480134208. Its NADAC has been published 106 times since Jun 19, 2024.
The High Outlier badge above means this manufacturer's average price in the Risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480134208
Classification
Generic
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA214068On Market Since
12/11/2023
Price Statistics
The NADAC for RISPERIDONE ER 37.5 MG VIAL has been published 106 times since Jun 19, 2024, and over the history we have for it it has declined 21.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $565.9133 per EA |
|---|---|
| All-time high | $732.9669 (Aug 13, 2025) |
| All-time low | $565.9133 (Jun 17, 2026) |
| 52-week high | $732.9669 |
| 52-week low | $565.9133 |
| Median price | $725.2341 |
| Average price | $716.7561 |
| Largest weekly change | -22.5% (Jun 17, 2026) |
| Weeks tracked | 106 |
| Tracking since | Jun 19, 2024 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 35% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of RISPERIDONE ER 37.5 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RISPERIDONE ER 37.5 MG VIAL, manufactured by Teva Pharmaceuticals USA Inc., is $565.9133 per EA (NDC 00480134208), effective Jun 24, 2026.
How has the price of RISPERIDONE ER 37.5 MG VIAL changed over time?
Over the history we have for it, the NADAC for RISPERIDONE ER 37.5 MG VIAL has declined 21.0%. It has been tracked across 106 weekly CMS publications since Jun 19, 2024.
What are the highest and lowest recorded NADAC prices for RISPERIDONE ER 37.5 MG VIAL?
Since Jun 19, 2024, the NADAC for RISPERIDONE ER 37.5 MG VIAL has ranged from a low of $565.9133 (Jun 17, 2026) to a high of $732.9669 (Aug 13, 2025), with a median of $725.2341 per EA.
Are there cheaper alternatives to RISPERIDONE ER 37.5 MG VIAL?
Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, RISPERIDONE ER 25 MG VIAL, is $369.6407 per EA — about 35% below RISPERIDONE ER 37.5 MG VIAL.
Who manufactures RISPERIDONE ER 37.5 MG VIAL?
RISPERIDONE ER 37.5 MG VIAL (NDC 00480134208) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification